Alliance, Milliman Partner to
Develop Real-World Evidence Metric
As the government's focus on healthcare value intensifies under the Inflation Reduction Act (IRA), questions are increasing about how organizations should best assess value.
In an effort to address the need for a transparent and sound methodology, the Alliance for Aging Research has partnered with Millimanto develop the Standard of Living Valuation (SoLV), a practical alternative to the Quality Adjusted Life Year (QALY) based on real-world evidence.
Alliance Gears Up to Celebrate Our Heroes in Health
Each year, the Alliance for Aging Research honors the advocates and changemakers who set the standard in research, innovation, and advocacy for older adults. This year, we are thrilled to celebrate the heroes that inspire our work.
As we make final preparations, be sure to follow #HeroesInHealth on social media and visit our website for updates on honoree announcements.
Join us on September 24 as we celebrate Hope, Resilience, and Healthy Aging at this year's Heroes in Health event at the beautiful Waldorf Astoria, Washington, D.C.
Podcast: Decoding the Inflation Reduction Act With Adina Lasser
“…all of these policies are treating patients as an amalgam, and every patient is an individual.”
On the latest episode of This Is Growing Old, we explore the implications of the IRA, along with the steps Centers for Medicare & Medicaid Services' (CMS) can take to protect beneficiaries with Alliance Public Policy Manager Adina Lasser.
The funding will support their project, “Pathways to Parity,” which aims to train individuals with Down syndrome and their caregivers in clinical and comparative effectiveness research.
Alliance and Partners Provide
Feedback on Cures 2.0
The Alliance and other supporters of the Twenty-First Century Cures Act recently provided feedback on Cures 2.0, highlighting the need for Congress to address medical device coverage.
They expressed concern that the proposed Transitional Coverage for Emerging Technologies (TCET) program by CMS would create barriers to care and emphasized the urgency of revising this pathway to avoid restrictive coverage limitations.
CMS' latest coverage policies will further decrease Medicare beneficiaries’ ability to access FDA-approved drugs, devices, and procedures covered under Medicare Part B, and would severely impact beneficiaries with life-threatening conditions.
Part D Plans Respond to Sign-On Letter Opposing Access Barriers to Vaccines for Older Adults
Part D plans responded to a May 2024 letter from 29 organizations urging CEOs of major health companies to avoid PBM deals in their June 2024 Medicare Part D contract bids that could limit vaccine access at in-network pharmacies during the respiratory virus season.
